Leukaemia Trial, Recruiting (NCT01252485)

Leukaemia Trial, Recruiting NCT01252485 Sponsor: University of Ulm Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT01252485 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have a suspected diagnosis of acute myeloid leukemia (a type of blood cancer) or a related blood condition, whether newly diagnosed or returning after previous treatment
You are 18 years of age or older (there is no maximum age limit)
You are willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

You have a serious neurological (brain or nervous system) or psychiatric (mental health) condition that would make it difficult for you to understand and agree to participate in the study
You do not agree to allow your personal and medical information to be recorded, stored, and shared with your family doctor as part of the study
You do not agree to allow samples of your biological material (such as blood or tissue) to be stored and used for future research testing

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hartmut Döhner, Prof. Dr., University Hospital of Ulm

Phone: 49-731-500-45501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT01252485

Sponsor: University of Ulm

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: 49-731-500-45501

More information: https://clinicaltrials.gov/study/NCT01252485

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have a suspected diagnosis of acute myeloid leukemia (a type of blood cancer) or a related blood condition, whether newly diagnosed or returning after previous treatment
You are 18 years of age or older (there is no maximum age limit)
You are willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

You have a serious neurological (brain or nervous system) or psychiatric (mental health) condition that would make it difficult for you to understand and agree to participate in the study
You do not agree to allow your personal and medical information to be recorded, stored, and shared with your family doctor as part of the study
You do not agree to allow samples of your biological material (such as blood or tissue) to be stored and used for future research testing

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Ulm

Registry

ClinicalTrials.gov

Start date

6 July 2010

Est. completion

31 December 2044

Where this trial is recruiting

🇦🇹 Austria 🇩🇪 Germany

Primary endpoints

incidence of disease-related genetic markers; Event-free survival; Cumulative incidence of relapse; Cumulative incidence of death; Overall survival; Treatment decision (intensive, non-intensive, investigational); quality of life; Geographical representation; Response to therapy; Relapse-free survival; Measurable residual disease (MRD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov